It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
We specialize in crafting stable, practical formulations that improve solubility, permeability, and bioavailability. With deep expertise across solid form science and formulation, we de-risk your compound and accelerate its path to first-in-human studies.
Poor solubility and permeability are common hurdles in drug development.
Our team designs formulations that tackle these issues head-on, enhancing both stability and bioavailability. By combining solid form and formulation expertise, we help you move confidently toward a viable clinical drug product.
We rigorously test every formulation prototype to ensure it meets the critical quality attributes (CQAs) aligned with the target product profile (TPP). And when you’re ready to scale, we support seamless technical transfer to your chosen Contract Development and Manufacturing Organization (CDMO).
Enhancing Bioavailability with Oral Formulation Approaches
To address solubility, permeability and bioavailability challenges in compounds, we employ several effective oral formulation strategies:
Lipid Based Formulation
Targeting hepatic and lymphatic systems, these are evaluated through in vitro lipolysis, flux determination, and stability assessments in capsules.
Particle Size Reduction
Creating micronized and nanosized dispersions to enhance dissolution properties.
Amorphous Spray Dried Dispersions (ASDs)
Tested for dissolution and flux, along with stability in capsules.
Nasal Formulations
Engineered to control dissolution rate for targeted delivery.
Injectable Formulation Approaches for Enhanced Solubility and Stability
For compounds requiring injectable delivery, we offer a range of formulation strategies that improve solubility, dose delivery, and long-term stability.
Lyophilized Buffer Solutions
Optimized lyophilization cycles reduce process time and cost while preserving formulation integrity.
Liposomal and EmulsionSystems
Advanced delivery systems that boost bioavailability and add valuable intellectual property to your program.
High-Concentration Solutions for Injection
Enable effective dosing for high drug-load compounds without compromising solubility or stability.
All injectable formulations undergo stability testing in Memmert chambers under ICH-like conditions (25°C/60%RH and 40°C/75%RH).
Why Choose Sygnature Discovery for Early Clinical Formulation Support?
Sygnature Discovery combines deep expertise across solid form science (including polymorph, salt, and co-crystal screening), formulation development, process chemistry, DMPK, and pharmacology. This integrated, cross-functional approach ensures that formulation decisions are scientifically robust and phase-appropriate. With pre-clinical and prototypic clinical formulation development capabilities all under one roof, projects can progress more rapidly into first-in-human studies. Sygnature Discovery also provides seamless technical transfer to your chosen CDMO, supporting smooth scale-up and manufacturing readiness.
Delve into the realm of targeted protein degradation and the critical role of formulation strategies in drug development. From overcoming dissolution limitations to optimizing stability and solubility, explore the key components that ensure your molecule’s clinical success. Sygnature Discovery offers comprehensive formulation support, bringing your degrader one step closer to achieving its full potential.
Sygnature has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at…
News
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
DMPK
Integrated DMPK solutions combining advanced assays, modeling, and bioanalysis delivering predictive insights that reduce risk and guide candidate selection.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
